Matt Kazan provides strategic advice to health plan and life sciences clients navigating the complex legislative and regulatory policy environment, with a particular expertise in Medicare Advantage and Medicare Part D. Prior to joining Avalere, Matt spent over a decade on the U.S. Senate Committee on Finance health staff under Senators Max Baucus and Ron Wyden.

As senior health policy adviser, Matt was the primary policy adviser on policy issues, including Medicare Advantage, Medicare Part D and all drug reimbursement under Medicare, chronic disease, dual eligibles, post-acute care, the Medicare Shared Savings Program, and Medicare and Medicaid program integrity. During his tenure, Matt was involved in a variety of major legislative efforts including the Affordable Care Act, the Bipartisan Budget Act of 2018, the Medicare Access and CHIP Reauthorization Act of 2015, the Children’s Health Insurance Program Reauthorization Act of 2009, and the American Recovery and Reinvestment Act. Matt holds an undergraduate degree from the University of Denver and a Master of Public Policy from the George Washington University.

Authored Content


Please join our panel of experts for an in-depth discussion of the rapidly evolving regulatory environment surrounding COVID-19 testing and treatment and the strategic, financial, and operational challenges this disease presents for health insurers.

In the fifth episode of this series, Avalere experts discuss how the pandemic could potentially shift the healthcare landscape and the policy debate.

The growing prevalence and disparities in chronic diseases necessitate that health plans address food insecurity to improve patient outcomes. The combination of increasing need for access to healthy food and changes in the health policy and insurance landscape create opportunities to address food insecurity through a variety of payers.

Avalere analysis finds that average beneficiary out-of-pocket (OOP) spending for 3 commonly used insulin products remains similar throughout the year, ranging from $95 in December to $136 in June and July.

Avalere analysis finds differences in the demographics of patients with End Stage Renal Disease (ESRD) enrolled in Medicare Advantage (MA) compared to ESRD patients in Fee-for-Service (FFS) Medicare

Avalere analysis finds that many CA beneficiaries enrolled in D-SNP look-alike plans may not be able to a transition to a D-SNP.

This month, the Centers for Medicare & Medicaid Services (CMS) proposed changes to Medicare Advantage (MA) through the annual Advance Rate Notice and Proposed Rule. These proposals impact MA in many ways, including changes to quality bonus payments, network adequacy requirements, coverage of End Stage Renal Disease (ESRD), plans targeting dual eligibles, and supplemental benefit offerings. Stakeholders should examine each of these areas closely as they respond to CMS.

CMS is set to release its annual proposed changes to Medicare Advantage (MA) this week. Some of the topics that may be addressed include End-Stage Renal Disease (ESRD), network adequacy requirements, payment to MA plans that offer the hospice benefit, and the MA quality bonus program.

Avalere analysis finds that payment to Medicare Advantage (MA) plans for end-stage renal disease (ESRD) patients in highly populated regions may be significantly below actual patient costs.

A shifting policy landscape and emerging market forces could introduce significant disruption in the kidney care space in the coming years. Understanding the risks and opportunities that these changes may present will be critical for patients, providers, payers, and manufacturers alike.